These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37159056)

  • 1. The crossroads: divergent roles of virus-specific CD4
    van Bockel D; Kelleher A
    Immunol Cell Biol; 2023 Jul; 101(6):525-534. PubMed ID: 37159056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk.
    Hewavisenti RV; Arena J; Ahlenstiel CL; Sasson SC
    Front Immunol; 2023; 14():1112513. PubMed ID: 36960048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.
    Farmer E; Cheng MA; Hung CF; Wu TC
    Recent Results Cancer Res; 2021; 217():157-195. PubMed ID: 33200366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
    Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
    Front Immunol; 2020; 11():188. PubMed ID: 32133000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer.
    Mensah FA; Mehta MR; Lewis JS; Lockhart AC
    Oncologist; 2016 Apr; 21(4):453-60. PubMed ID: 26961923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
    Rambout L; Hopkins L; Hutton B; Fergusson D
    CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China.
    Chen M; Li C; Cui Q; Zhou C; Chen P; Yao S
    Eur J Obstet Gynecol Reprod Biol; 2023 Jul; 286():10-15. PubMed ID: 37159990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of genital human papillomavirus infection in a female adolescent population.
    Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM
    Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for preventing HPV-related anogenital infection and neoplasia.
    Ferris DG
    J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
    Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
    Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
    Joura EA; Leodolter S; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Garland SM; Harper DM; Tang GW; Ferris DG; Steben M; Jones RW; Bryan J; Taddeo FJ; Bautista OM; Esser MT; Sings HL; Nelson M; Boslego JW; Sattler C; Barr E; Paavonen J
    Lancet; 2007 May; 369(9574):1693-702. PubMed ID: 17512854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
    Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.
    Tong WW; Shepherd K; Garland S; Meagher A; Templeton DJ; Fairley CK; Jin F; Poynten IM; Zaunders J; Hillman RJ; Grulich AE; Kelleher AD; Carr A;
    J Infect Dis; 2015 Feb; 211(3):405-15. PubMed ID: 25139018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.
    Guo T; Eisele DW; Fakhry C
    Cancer; 2016 Aug; 122(15):2313-23. PubMed ID: 27152637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.
    Zurek Munk-Madsen M; Toft L; Kube T; Richter R; Ostergaard L; Søgaard OS; Tolstrup M; Kaufmann AM
    Hum Vaccin Immunother; 2018 Apr; 14(4):909-916. PubMed ID: 29172992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chapter 17: Genital human papillomavirus infections--current and prospective therapies.
    Stanley M
    J Natl Cancer Inst Monogr; 2003; (31):117-24. PubMed ID: 12807955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.